Influenza vaccine trivalent - Seqirus

Drug Profile

Influenza vaccine trivalent - Seqirus

Alternative Names: Afluria; Enzira; Fluvax; Inactivated Influenza Vaccine; Nilgrip

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator CSL
  • Developer Seqirus
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 05 Jul 2016 Seqirus plans an Enhanced Passive Safety Surveillance clinical trial for Influenza virus infections (Prevention) in United Kingdom (IM) (UKCRN30538)
  • 09 Nov 2015 CSL’s influenza vaccine business started operating under the brand name Seqirus
  • 01 Sep 2014 CSL initiates a phase IV trial for Influenza virus infections (Prevention, In children) in USA (NCT02212106)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top